No Data
No Data
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
Castle Biosciences Honored With a Top Workplaces USA Award for Fourth Consecutive Year
Castle Biosciences Announced The Recent Publication Of Two Papers In The World Journal Of Surgical Oncology And Cancer Medicine Sharing Reports From The Prospective, Multicenter Decide Study Demonstrating The Significant Impact Of The Company's...
Publication of Data From Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients With Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy With Information From Castle Biosciences' DecisionDx-Melanoma Test
Castle Biosciences Announces It Will Present New Data At EADO April 3-5, 2025 In Athens, Greece Supporting The Clinical Value of the DecisionDx Melanoma Test in Guiding Risk-Aligned Management Of Patients With Melanoma